Shanghai Kaibao Pharmaceutical (300039) - Total Assets

Latest as of June 2026: CN¥4.59 Billion CNY ≈ $672.24 Million USD

Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) holds total assets worth CN¥4.59 Billion CNY (≈ $672.24 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Shanghai Kaibao Pharmaceutical - Total Assets Trend (2006–2025)

This chart illustrates how Shanghai Kaibao Pharmaceutical's total assets have evolved over time, based on quarterly financial data. Also see Shanghai Kaibao Pharmaceutical market capitalisation for the company's overall valuation and market capitalisation.

Shanghai Kaibao Pharmaceutical - Asset Composition Analysis

Current Asset Composition (December 2025)

Shanghai Kaibao Pharmaceutical's total assets of CN¥4.59 Billion consist of 46.8% current assets and 53.2% non-current assets. Review 300039 liabilities breakdown to assess the company's total debt and financial obligations.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	20.5%
Accounts Receivable	CN¥292.08 Million	6.1%
Inventory	CN¥200.41 Million	4.2%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥163.57 Million	3.4%
Goodwill	CN¥0.00	0.0%

Asset Composition Trend (2006–2025)

This chart illustrates how Shanghai Kaibao Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Shanghai Kaibao Pharmaceutical stock quote for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Shanghai Kaibao Pharmaceutical's current assets represent 46.8% of total assets in 2025, a decrease from 70.3% in 2006.
Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, up from 5.3% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2006.
Asset Diversification: The largest asset category is accounts receivable at 6.1% of total assets.

Shanghai Kaibao Pharmaceutical Competitors by Total Assets

Key competitors of Shanghai Kaibao Pharmaceutical based on total assets are shown below.

Company	Country	Total Assets
Kamada TA:KMDA	Israel	ILA377.21 Million
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	USA	$15.42 Trillion
Viatris Inc NASDAQ:VTRS	USA	$35.04 Billion
Takeda Pharmaceutical Company Limited F:TKDA	Germany	€15.41 Trillion
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	China	CN¥14.18 Billion
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	China	CN¥10.21 Billion
Yipinhong Pharmaceutical Co Ltd Class A SHE:300723	China	CN¥4.49 Billion
Avadel Pharmaceuticals PLC NASDAQ:AVDL	USA	$199.45 Million

Shanghai Kaibao Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	13.36	12.62	11.53
Quick Ratio	11.81	11.62	10.52
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥1.71 Billion	CN¥2.35 Billion	CN¥2.02 Billion

Shanghai Kaibao Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Shanghai Kaibao Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.27
Latest Market Cap to Assets Ratio	0.16
Asset Growth Rate (YoY)	5.8%
Total Assets	CN¥4.78 Billion
Market Capitalization	$771.44 Million USD

Valuation Analysis

Below Book Valuation: The market values Shanghai Kaibao Pharmaceutical's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Shanghai Kaibao Pharmaceutical's assets grew by 5.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Shanghai Kaibao Pharmaceutical (2006–2025)

The table below shows the annual total assets of Shanghai Kaibao Pharmaceutical from 2006 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥4.78 Billion ≈ $699.22 Million	+5.75%
2024-12-31	CN¥4.52 Billion ≈ $661.19 Million	-1.34%
2023-12-31	CN¥4.58 Billion ≈ $670.15 Million	+7.52%
2022-12-31	CN¥4.26 Billion ≈ $623.27 Million	+26.92%
2021-12-31	CN¥3.36 Billion ≈ $491.06 Million	+16.63%
2020-12-31	CN¥2.88 Billion ≈ $421.04 Million	+1.22%
2019-12-31	CN¥2.84 Billion ≈ $415.95 Million	+3.46%
2018-12-31	CN¥2.75 Billion ≈ $402.03 Million	+2.53%
2017-12-31	CN¥2.68 Billion ≈ $392.13 Million	+6.01%
2016-12-31	CN¥2.53 Billion ≈ $369.91 Million	+4.17%
2015-12-31	CN¥2.43 Billion ≈ $355.10 Million	+14.61%
2014-12-31	CN¥2.12 Billion ≈ $309.84 Million	+19.57%
2013-12-31	CN¥1.77 Billion ≈ $259.13 Million	+13.43%
2012-12-31	CN¥1.56 Billion ≈ $228.44 Million	+7.48%
2011-12-31	CN¥1.45 Billion ≈ $212.53 Million	+5.98%
2010-12-31	CN¥1.37 Billion ≈ $200.53 Million	+1.86%
2009-12-31	CN¥1.35 Billion ≈ $196.87 Million	+485.27%
2008-12-31	CN¥229.88 Million ≈ $33.64 Million	+42.24%
2007-12-31	CN¥161.61 Million ≈ $23.65 Million	+48.22%
2006-12-31	CN¥109.03 Million ≈ $15.96 Million	--

About Shanghai Kaibao Pharmaceutical

SHE:300039 China Drug Manufacturers - Specialty & Generic

Market Cap

$771.44 Million

CN¥5.27 Billion CNY

Market Cap Rank

#10125 Global

#2666 in China

Share Price

CN¥5.04

Change (1 day)

+0.60%

52-Week Range

CN¥4.18 - CN¥6.66

All Time High

CN¥12.44